Axa trimmed its position in shares of Waters Corporation (NYSE:WAT) by 21.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 38,795 shares of the medical instruments supplier’s stock after selling 10,405 shares during the quarter. Axa’s holdings in Waters Corporation were worth $7,132,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. Wells Fargo & Company MN boosted its position in Waters Corporation by 25.7% during the 2nd quarter. Wells Fargo & Company MN now owns 124,782 shares of the medical instruments supplier’s stock valued at $22,940,000 after acquiring an additional 25,506 shares in the last quarter. Edgestream Partners L.P. boosted its position in Waters Corporation by 29.6% during the 2nd quarter. Edgestream Partners L.P. now owns 4,956 shares of the medical instruments supplier’s stock valued at $911,000 after acquiring an additional 1,131 shares in the last quarter. Franklin Resources Inc. boosted its position in Waters Corporation by 3.1% during the 2nd quarter. Franklin Resources Inc. now owns 927,227 shares of the medical instruments supplier’s stock valued at $170,461,000 after acquiring an additional 28,229 shares in the last quarter. Tredje AP fonden boosted its position in Waters Corporation by 247.2% during the 2nd quarter. Tredje AP fonden now owns 12,430 shares of the medical instruments supplier’s stock valued at $2,285,000 after acquiring an additional 8,850 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. bought a new stake in Waters Corporation during the 2nd quarter valued at approximately $1,339,000. 91.12% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have weighed in on WAT. Bank of America Corporation reaffirmed a “neutral” rating and set a $192.00 price objective (up from $180.00) on shares of Waters Corporation in a research report on Friday, July 21st. Deutsche Bank AG cut Waters Corporation from a “buy” rating to a “hold” rating and lifted their price objective for the company from $183.00 to $194.00 in a research report on Monday, July 10th. Jefferies Group LLC reaffirmed a “hold” rating and set a $175.00 price objective on shares of Waters Corporation in a research report on Thursday, August 31st. Cowen and Company reaffirmed a “hold” rating and set a $190.00 price objective on shares of Waters Corporation in a research report on Friday, July 14th. Finally, Zacks Investment Research cut Waters Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Waters Corporation currently has a consensus rating of “Hold” and a consensus price target of $186.00.
Waters Corporation (NYSE WAT) opened at 189.29 on Friday. The stock has a market capitalization of $15.11 billion, a price-to-earnings ratio of 28.53 and a beta of 0.83. Waters Corporation has a one year low of $133.35 and a one year high of $190.39. The company has a 50-day moving average of $180.64 and a 200-day moving average of $173.26.
Waters Corporation (NYSE:WAT) last released its quarterly earnings data on Tuesday, July 25th. The medical instruments supplier reported $1.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.71 by $0.05. Waters Corporation had a net margin of 24.26% and a return on equity of 23.91%. The firm had revenue of $558.30 million for the quarter, compared to the consensus estimate of $553.22 million. During the same period last year, the firm earned $1.58 earnings per share. The company’s quarterly revenue was up 4.0% on a year-over-year basis. On average, equities analysts forecast that Waters Corporation will post $7.38 EPS for the current fiscal year.
In related news, SVP Rohit Khanna sold 18,400 shares of the stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $185.78, for a total transaction of $3,418,352.00. Following the completion of the sale, the senior vice president now owns 22,477 shares of the company’s stock, valued at $4,175,777.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher A. Kuebler sold 3,500 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $179.67, for a total transaction of $628,845.00. Following the sale, the director now directly owns 17,849 shares of the company’s stock, valued at approximately $3,206,929.83. The disclosure for this sale can be found here. 5.07% of the stock is currently owned by company insiders.
Waters Corporation Profile
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.
Receive News & Ratings for Waters Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters Corporation and related companies with MarketBeat.com's FREE daily email newsletter.